Logo

BNTX

BioNTech SE

BNTX

BioNTech SE • NASDAQ
$103.15 ▲ 0.44% (+0.45)
Market Cap $24.80 B
52w High $129.27
52w Low $81.20
Dividend Yield 0%
P/E -37.24
Volume 822.27K
Outstanding Shares 240.46M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.519B ▲ $1.417B ▲ $-28.7M ▲ -1.89% ▲ $-0.12 ▲ $149.299M ▲
Q2-2025 $260.8M ▲ $685.5M ▲ $-386.6M ▲ -148.236% ▲ $-1.6 ▲ $-348.3M ▲
Q1-2025 $182.8M ▼ $633.1M ▼ $-415.8M ▼ -227.462% ▼ $-1.73 ▼ $-368.7M ▼
Q4-2024 $1.19B ▼ $797.9M ▼ $259.5M ▲ 21.807% ▲ $1.08 ▲ $464.4M ▲
Q3-2024 $1.245B $1.055B $198.1M 15.914% $0.83 $211.1M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $14.528B ▲ $21.341B ▼ $2.864B ▼ $18.477B ▼
Q2-2025 $14.037B ▼ $21.638B ▲ $3.132B ▲ $18.505B ▼
Q1-2025 $14.11B ▼ $21.182B ▼ $2.256B ▼ $18.927B ▼
Q4-2024 $16.784B ▲ $22.53B ▲ $3.119B ▼ $19.411B ▲
Q3-2024 $16.709B $22.401B $3.287B $19.114B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-33.537M ▲ $854.59M ▲ $-995.852M ▼ $-14.029M ▲ $-195.695M ▼ $811.136M ▲
Q2-2025 $-438.53M ▼ $132.137M ▲ $-26.671M ▼ $-14.94M ▼ $1.053B ▲ $700.035M ▲
Q1-2025 $-437.614M ▼ $-821.658M ▼ $1.312B ▲ $-14.524M ▼ $893.282M ▲ $-1.472B ▼
Q4-2024 $276.807M ▲ $-501.207M ▲ $649.243M ▲ $-8.09M ▲ $-633.087M ▼ $-601.695M ▲
Q3-2024 $217.622M $-687.848M $-162.624M $-8.665M $-379.693M $-778.73M

Five-Year Company Overview

Income Statement

Income Statement BioNTech’s income statement shows a company coming off an exceptional, one‑off boom and moving into a tougher, more normal phase. Revenues and profits surged during the COVID‑19 vaccine peak, with very high margins, but they have since fallen sharply as demand normalized and pricing/volumes came down. The business has now swung from strong profitability to operating and net losses, reflecting lower COVID revenue and much heavier investment in research, development, and infrastructure. Overall, earnings are currently volatile and under pressure as the company transitions from a single blockbuster toward a broader portfolio.

Balance Sheet

Balance Sheet The balance sheet is a key strength. The company holds a large cash and investment cushion relative to its very low debt, and equity has been built up substantially from past COVID‑era profits. This gives BioNTech considerable flexibility to fund R&D, clinical trials, and manufacturing expansion without relying heavily on borrowing. The main risk is not financial fragility, but whether that strong balance sheet is deployed into projects that ultimately generate sustainable new revenue streams.

Cash Flow

Cash Flow Cash flow has followed a similar pattern: extremely strong during the vaccine boom, now moderating significantly. Operating cash inflows remain positive but much smaller than at the peak, while free cash flow recently dipped slightly negative as capital spending and pipeline investments ramp up. In plain terms, the company is consciously reinvesting its past windfall into future products, which tightens near‑term cash flow but is affordable given its cash reserves. The sustainability of cash generation will increasingly depend on new oncology and infectious‑disease products reaching market.

Competitive Edge

Competitive Edge BioNTech holds a strong but evolving competitive position. Its early success with the COVID‑19 vaccine, deep mRNA know‑how, and high scientific reputation give it strong brand recognition and credibility with regulators, partners, and talent. Strategic alliances with large pharma players like Pfizer, Roche/Genentech, and others extend its commercial reach and de‑risk some development. However, competition in mRNA and immuno‑oncology is intense, the patent landscape is contentious, and rivals like Moderna and big pharma are pursuing similar targets, so leadership is not guaranteed and will be decided by clinical data and execution over the next several years.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of BioNTech’s story. The company is leveraging multiple mRNA platforms, personalized and off‑the‑shelf cancer vaccines, cell therapies (such as CAR‑T), and advanced immunotherapies, aiming to turn its COVID‑era proof of concept into a broad oncology and infectious‑disease franchise. This breadth of platforms, together with founder‑led scientific leadership and significant manufacturing investments, forms a meaningful technological moat. The flip side is that heavy R&D and clinical spending now weigh on profits, and there is substantial scientific and regulatory risk: many programs may not succeed, and timelines can be long and uncertain.

Summary

BioNTech is in a transition from being predominantly a COVID‑19 vaccine beneficiary to a diversified, innovation‑driven biotech focused on cancer and other serious diseases. Financially, it moves from extraordinary, temporary profitability to a phase of lower revenue, losses, and heavy reinvestment, though supported by a very strong cash and balance sheet position. Competitively, it has genuine strengths in mRNA technology, partnerships, and scientific leadership, but faces fierce competition and execution risk as the field matures. The next chapter depends on whether its broad pipeline—especially in oncology and new vaccines—can convert today’s R&D spending and cash reserves into durable, post‑COVID revenue and more stable long‑term earnings.

NEWS

November 26, 2025 · 7:30 AM UTC

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Read more

November 3, 2025 · 6:45 AM UTC

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Read more

October 28, 2025 · 7:45 AM UTC

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Read more

October 27, 2025 · 7:45 AM UTC

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Read more

October 22, 2025 · 6:45 AM UTC

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Read more